Approximately 400 OINDP experts gathered in Orlando, FL, USA May 1-May 5 for the first in-person Respiratory Drug Delivery meeting since 2019, with another 75 attending virtually. RDD Online's Richard Dalby welcomed delegates from 28 countries to the meeting in a full ballroom at the Omni Championsgate. Throughout the meeting, delegates expressed how happy they were … [Read more...] about RDD 2022 returned with the latest in OINDP technology
News
SoftOx reports positive Phase 1 results for its hypochlorous acid inhalation solution
SoftOx Solutions has announced that a Phase 1 study of its SoftOx inhalation solution (SIS) demonstrated that nebulized SIS was well tolerated with no serious adverse effects observed and no adverse effects related to pulmonary function. The study enrolled 57 healthy volunteers who got either SIS or placebo delivered via jet nebulizer 4 times per day for 5 days, with … [Read more...] about SoftOx reports positive Phase 1 results for its hypochlorous acid inhalation solution
Moderna highlights partnership with Vertex on inhaled mRNA therapy for CF
According to Moderna Therapeutics, the company used its annual "Science and Technology Day" to highlight its work on lipid nanoparticle (LNP) mRNA formulations, and CEO Stéphane Bancel made special note of the company's advances in pulmonary delivery, including a partnership with Vertex on development of an inhaled mRNA formulation that could give CF patients the … [Read more...] about Moderna highlights partnership with Vertex on inhaled mRNA therapy for CF
Aston Particle Technologies gets £1 million in funding
Aston University spin out Aston Particle Technologies (APT) has closed a £1 million funding round according to lead investor DSW Ventures. The funding will be used for scale up of APT's isothermal dry particle coating (iDPC) technology, which DSW said is useful for high dose DPI formulations among other uses. DSW explained that the expanded cGMP capacity is necessary … [Read more...] about Aston Particle Technologies gets £1 million in funding
Spirovant opens new lab and headquarters
Sumitovant subsidiary Spirovant Sciences, which is developing inhaled gene therapies for the treatment of cystic fibrosis, has opened a new research laboratory and corporate headquarters in Philadelphia, PA, USA, the company said. Spirovant's SP-101 inhaled adeno-associated virus (AAV) gene therapy for CF has been granted orphan disease and rare pediatric disease … [Read more...] about Spirovant opens new lab and headquarters
Positive Phase 1 results for Pneumagen’s Neumifil antiviral nasal spray
Pneumagen has announced that a Phase 1 dose escalation study of its Neumifil carbohydrate binding module nasal spray demonstrated that the nasal spray was well tolerated and had no dose limiting toxicity. Pneumagen announced the initiation of the Phase 1 trial in November 2021. The company previously announced data from pre-clinical studies showing that Neumifil has … [Read more...] about Positive Phase 1 results for Pneumagen’s Neumifil antiviral nasal spray
Alembic gets FDA approval for its arforoterol tartrate inhalation solution
According to Indian generics developer Alembic Pharmaceuticals, the company's ANDA for a generic version of Sunovion's Brovana arformoterol tartrate inhalation solution for the treatment of COPD has received final FDA approval. Alembic co-developed the arformoterol inhalation solution with Indian CRO Orbicular Pharmaceutical Technologies. The ANDA approval is … [Read more...] about Alembic gets FDA approval for its arforoterol tartrate inhalation solution
Pieris warns of potential delays in clinical trial of PRS-060/AZD1402 DPI
In a business update, Pieris Pharmaceuticals warned that an ongoing clinical trial of its dry powder PRS-060/AZD1402 IL-4 receptor alpha inhibitor may take longer than expected, saying "Given the geopolitical situation, along with broader challenges amidst an ongoing pandemic, there is a heightened risk that more time will be required to deliver the topline study … [Read more...] about Pieris warns of potential delays in clinical trial of PRS-060/AZD1402 DPI
Nebu-Flow closes £1.7 million funding round
Scottish nebulizer developer Nebu-Flow has raised £1.7 million "to continue the commercialization and delivery of next generation respiratory pharmaceuticals," the company has announced on social media. The funding round was led by Foresight Williams Technology. Nebu-Flow was spun out from the University of Glasgow in 2019 to develop a device based on surface acoustic … [Read more...] about Nebu-Flow closes £1.7 million funding round
Zeteo Biomedical launches ZEOx1 OrionMRQ nasal delivery device
Zeteo Biomedical has announced the launch of its ZEOx1 OrionMRQ metered dose nasal device for delivery of drugs and vaccines. Zeteo's ZEOx1 devices are designed for intranasal delivery of liquid formulations, and its ZEOx2 devices are designed for intranasal delivery of powders, reconstituted powders, or multiple liquid formulations. In November 2020, Zeteo said that … [Read more...] about Zeteo Biomedical launches ZEOx1 OrionMRQ nasal delivery device